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original article

Surveillance for Vancomycin-Resistant Enterococci:
Type, Rates, Costs, and Implications
Brooke N. Shadel, PhD, MPH; Laura A. Puzniak, PhD, MPH; Kathleen N. Gillespie, PhD; Steven J. Lawrence, MD;
Marin Kollef, MD; Linda M. Mundy, MD

objective. To evaluate 2 active surveillance strategies for detection of enteric vancomycin-resistant enterococci (VRE) in an intensive
care unit (ICU).
design.

Thirty-month prospective observational study.

setting.

ICU at a university-affiliated referral center.

patients.

All patients with an ICU stay of 24 hours or more were eligible for the study.

intervention. Clinical active surveillance (CAS), involving culture of a rectal swab specimen for detection of VRE, was performed
on admission, weekly while the patient was in the ICU, and at discharge. Laboratory-based active surveillance (LAS), involving culture of
a stool specimen for detection of VRE, was performed on stool samples submitted for Clostridium difficile toxin detection.
results. Enteric colonization with VRE was detected in 309 (17%) of 1,872 patients. The CAS method initially detected 280 (91%) of
the 309 patients colonized with VRE, compared with 25 patients (8%) detected by LAS; colonization in 4 patients (1%) was initially detected
by analysis of other clinical specimens. Most patients with colonization (76%) would have gone undetected by LAS alone, whereas use of
the CAS method exclusively would have missed only 3 patients (1%) who were colonized. CAS cost $1,913 per month, or $57,395 for the
30-month study period. Cost savings of CAS from preventing cases of VRE colonization and bacteremia were estimated to range from
$56,258 to $303,334 per month.
conclusions. A patient-based CAS strategy for detection of enteric colonization with VRE was superior to LAS. In this high-risk setting,
CAS appeared to be the most efficient and cost-effective surveillance method. The modest costs of CAS were offset by the averted costs
associated with the prevention of VRE colonization and bacteremia.
Infect Control Hosp Epidemiol 2006; 27:1068-1075

Infections caused by multidrug-resistant organisms are associated with increased morbidity and mortality,1-11 prolonged
hospital stays, and excess costs.9,12-14 Adverse effects of infection with multidrug-resistant organisms lead not only to
higher healthcare costs but also to higher societal costs in
terms of decreased productivity and quality of life for patients
and their families.15 Because enteric colonization with vancomycin-resistant enterococci (VRE) is an important risk factor for VRE infection, prevention of colonization through
identification of others who are colonized, followed by implementation of measures to control the spread of VRE after
their identification, seem imperative.9,16-19
Existing guidelines recommend that healthcare facilities develop and implement a plan to prevent and control the spread
of VRE.9,20 However, definitive recommendations regarding
methods of surveillance have not been determined. Although

the costs of surveillance for enteric VRE have only begun to
be described,5,21,22 the attributable costs to the healthcare system associated with VRE bacteremia alone may justify surveillance and control programs.5,7,8,13,23,24 Identification of
VRE-colonized patients and implementation of contact isolation have been shown to be cost-effective and may reduce
VRE-related morbidity and mortality in populations at highrisk for VRE acquisition.5,6,23,25-28
A variety of active and passive surveillance methods have
been used for detection of enteric VRE.5,15,22,24,29-34 A few studies have compared active surveillance methods but were unable to conclude which method was superior.31,32,34 The objectives of this study were to compare the performance of 2
active surveillance strategies for detection of enteric VRE and
to describe the associated costs and implications of these
strategies.

From the Institute for Bio-Security, School of Public Health, Saint Louis University (B.N.S., L.M.M), the Saint Louis County Health Department (L.A.P.),
the Department of Health Management and Policy, School of Public Health, Saint Louis University (K.N.G.), and the Divisions of Infectious Diseases (S.J.L.)
and Pulmonary and Critical Care Medicine (M.K.), Washington University School of Medicine, St. Louis, Missouri.
Received August 18, 2005; accepted December 29, 2005; electronically published September 21, 2006.
䉷 2006 by The Society for Healthcare Epidemiology of America. All rights reserved. 0899-823X/2006/2710-0011$15.00.
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table 1. Demographic and Clinical Characteristics of 1,872 Intensive Care Unit
Patients by Vancomycin-Resistant Enterococci (VRE) Colonization Status
Colonization status of patients
Variable
Categorical
White race
Male sex
Bacteremia, by causal pathogen
MRSA
Pseudomonas aeruginosa
Clostridium difficile
Mortality
Continuous
Age, y
Duration of MICU stay, db
Duration of hospitalization, db
APACHE II scorec

VRE prevalenta
(n p 182)

VRE incident
(n p 127)

VRE negative
(n p 1,563)

109 (60.0)
74 (40.7)

73 (57.5)
59 (46.5)

867 (55.5)
761 (48.7)

14
4
15
47

126
26
70
396

14
3
8
79

(7.7)
(1.6)
(4.4)
(43.4)

62.3 Ⳳ 17.6
7.5 Ⳳ 8.7
23.2 Ⳳ 31.2
24.4 Ⳳ 7.5

(11.0)
(3.1)
(11.8)
(37.0)

62.5 Ⳳ 15.9
16.9 Ⳳ 18.5
33.7 Ⳳ 27.8
23.9 Ⳳ 6.3

(8.1)
(1.7)
(4.5)
(25.3)

58.9 Ⳳ 17.9
5.5 Ⳳ 7.6
14.7 Ⳳ 19.8
21.1 Ⳳ 8.2

note. Data are no. (%) of patients or mean value Ⳳ SD. See Methods for definitions of
colonization status. APACHE, Acute Physiology and Chronic Health Evaluation; MICU, medical
intensive care unit; MRSA, methicillin-resistant Staphylococcus aureus.
a
Four patients with VRE initially detected in culture of a nonsurveillance clinical isolate (ie,
culture of sterile body fluid, performed as a component of routine clinical care) were categorized
as having VRE identified through CAS.
b
Defined as the time of admission through the time of discharge.
c
From Knaus et al.41

me th ods
Setting and Patients
Eligible participants were all patients admitted from July 1,
1997, through December 31, 1999, to the 19-bed medical
intensive care unit (ICU) at Barnes-Jewish Hospital (BJH), a
1,287-bed tertiary care facility in St. Louis, Missouri. Data
on patients residing in the ICU for 24 hours or more were
included; data from multiple admissions were combined if
subsequent admissions occurred 30 days or less after the initial admission. Data from only the first admission were included in the analysis if subsequent admissions occurred more
than 30 days after the initial admission. Patients were excluded if microbiological data were incomplete or the patients’ medical records could not be reviewed. The research
review committees at Saint Louis University (St. Louis) and
Washington University Medical Center (St. Louis) approved
this study.
Study Design and Definitions
Clinical active surveillance (CAS) for VRE was defined as
prospective screening using rectal swab specimens. The CAS
method was performed by clinical staff who procured specimens for detection of enteric VRE from all ICU patients at
ICU admission, ICU discharge, and every 7 days if the ICU
stay was 7 days or longer. Laboratory-based active surveillance
(LAS) was defined as screening of clinical stool specimens for
VRE that were originally collected for Clostridium difficile

screening in accordance with hospital-wide policy established
on October 1, 1996.35 Patients with enteric VRE initially detected in culture of a nonsurveillance clinical isolate (ie, culture
of sterile body fluid, performed as a component of routine
clinical care) were categorized as having VRE identified through
clinical specimens. Stool samples submitted by 12 patients for
C. difficile testing at the time of admission were classified as
CAS specimens. Patients with a stool specimen positive for C.
difficile toxin by cytotoxicity assay (Bartels) were categorized
as having C. difficile–associated diarrhea or colitis.
Patients with VRE detected by surveillance or clinical culture before or on admission to the ICU were classified as
having a prevalent case of VRE colonization. Patients with
enteric VRE acquired during ICU stay were characterized as
having an incident case of VRE colonization. Patients with
negative culture results from the time of admission through
the time of discharge were classified as being VRE negative.
The incidence density was calculated by dividing the number
of patients with an incident case of VRE colonization by the
number of inpatient-days in the ICU from either admission
until discharge (for patients without VRE colonization) or
from admission until the date of initial VRE detection (for
patients with VRE colonization).
Data Collection
During the study period, differential infection control strategies were used for the scheduled rotation of antimicrobial
therapy and gown use, as described elsewhere.6,29 Cost data

1070

infection control and hospital epidemiology

october 2006, vol. 27, no. 10

table 2. Costs Attributable to Clinical Active Surveillance (CAS) and Laboratory-Based Active
Surveillance (LAS) Programs for Detection of Vancomycin-Resistant Enterococci
Unit
cost

Cost variable
Labor costs
Nursing time (6 min per specimen)
Laboratory technologists’ time
9.6 min per negative culture result
15.9 min per positive culture result
Supply costs
Fixed negative surveillance test results
Fixed positive specimens
Processing costs
Initial laboratory cost per culture
Extra laboratory cost per positive culture result
Stool collection cups
Swabs
Hand hygienec
Gloves
Total cost per negative test result
Total cost per positive test result
Total cost of surveillance program
Total cost of surveillance program in 2003 US dollars
Monthly cost of surveillance program in 2003 US dollars
Cost of surveillance program per patient in 2003 US dollarsd

CAS costs
over 30 mo
(3,224 tests)a

LAS costs
over 30 mo
(562 tests)b

2.70

8,705

1,517

2.78
4.97

7,542
2,540

1,187
671

5.00
13.00

13,565
6,643

2,135
1,755

1.20
1.97
0.07
0.28
0.10
0.07
12.13
24.29
…
…
…
…

3,869
1,007
NA
903
322
226
…
…
45,321
57,395
1,913
30.66

674
266
40
NA
56
39
…
…
8,341
10,563
352
5.64

note. Costs are in 1997 US dollars, unless otherwise indicated. Costs in columns indicating totals have been
rounded. See Methods for definitions of CAS and LAS. NA, not applicable.
a
A total of 2,713 negative test results and 551 positive test results.
b
A total of 427 negative test results and 135 positive test results.
c
Comprised the cost of alcohol foam and of soap and water with paper towels.
d
Of 1,872 patients who met the study criteria, 759 were excluded because they had a stay of less than 24 hours
(748 patients) or had incomplete data (11 patients).

were harvested through the hospital laboratory information
system and the hospital informatics system.36
Cost Data
Program costs were obtained from 2 clinical databases and
1 cost administrative database. Costs, rather than charges,
were used because they represent the cost to the institution
undertaking a surveillance program. The cost data were harvested in 1997 and 1998 US dollars, reflecting the value of
the US dollar during the study period. The total costs of the
surveillance program were converted to 2003 US dollars using
the medical care component of the Consumer Price Index37
and are reported in the text in 2003 US dollars.
Labor, supply, and processing costs were reported for cultures with positive results and cultures with negative results.
Labor costs included estimated staff expenditures. The cost
of the technologists’ time to receive, process, finalize, and
report the specimen was converted to dollars, using the mean
salary of a technologist at BJH in 1997, and added into the
final cost of the test. The amount of time spent for specimen
procurement by healthcare personnel was estimated to be 6
minutes per specimen. The mean hourly wage, excluding

fringe benefits, calculated for the staff collecting the specimens was $27.00 in 1998 (study midpoint). The combined
costs for the performance of hand hygiene before and after
each patient encounter was estimated to be $0.10. The supply
costs included the fixed costs per test that did not vary with
the volume of testing.
Estimated Cost Savings
Detection of VRE should lead to fewer cases of colonization
and bacteremia and, therefore, lower costs of hospitalization.
To estimate the cost savings associated with averted cases,
transmission of VRE was varied between a predictive rate of
0.5 and 2 times the rate.38 The proportion of VRE-colonized
patients who became bacteremic in this study was 7.8%,
slightly lower than the rates of up to 13.4% reported in 3
distinct oncology populations.16,18,39 These differential rates
were used to estimate the number of at-risk bacteremic patients. The excess cost of each case of VRE colonization was
estimated using the values $3,06525 and $9,97040 (both in 2003
dollars) obtained from the literature. The excess healthcare
cost of each case of VRE bacteremia was estimated as $17,1438
and $36,380.13
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table 3. Clinical and Epidemiological Characteristics of Vancomycin-Resistant Enterococci (VRE)
Colonization Among 1,872 Patients Over a 30-Month Surveillance Period

Variable
Cultures performed, no.
Overall
Negative results
Positive results
Patients with VRE detected, no.
Overall
Detected at admission
Detected during hospital stay
Patients with no VRE detected, no.
During hospital stay
At admission
Patients with bacteremia but no VRE detected, no.
Transmission dynamic of undetected VREa
0.50
2.00
Likelihood of colonized patient becoming
bacteremica
0%
7.8%
13%

CAS and
LAS

CAS

LAS

Surveillance
at admission
only

3,786
3,140
646

2,684
2,173
511

575
427
148

1,734
1,552
182

309
182
127

306
182
124

75
38
37

182
182

0
0
0

3
0
0

234
144
9

127
0
10

⫺190.5
⫺381

0
⫺20
⫺33

⫺186
⫺372

0
⫺19.5
⫺32.22

160.5
321

Referent
Referent

0
17
28

Referent
Referent
Referent

note. See Methods for definitions of clinical active surveillance (CAS) and laboratory-based active surveillance
(LAS).
a
Number of patients colonized as a result of contact with a colonized patient. The value 7.8% is from Puzniak
et al.29; the value 13% is from Leber et al.,22 Mayhall et al.,23 and Hachem et al.24

Statistical Analysis
SPSS statistical software, version 11.0 (SPSS), was used for
all analyses. Descriptive analyses were performed, including
analyses of frequencies, mean values, and median values.

res ults
Patients
Of 2,631 admitted patients, 1,872 (71%) met the study criteria; 748 patients (28%) with an ICU stay of less than 24
hours and 11 patients with incomplete or missing medical
records were excluded. Demographic and clinical characteristics by VRE colonization status are reported in Table 1. The
mean length of ICU stay (ⳲSD) for the study cohort was
6.7 Ⳳ 9.3 days, although a prolonged mean duration of ICU
stay (ⳲSD) of 16.9 Ⳳ 18.5 days was observed for patients
with incident enteric colonization with VRE. Few patients
(less than 10%) had coexisting methicillin-resistant Staphylococcus aureus or Pseudomonas aeruginosa bacteremia. Overall crude mortality was 28% and was higher among patients
with enteric VRE.
Surveillance
A total of 3,224 rectal swab specimens and 562 stool specimens were tested for VRE (Table 2). Patients who acquired

VRE had approximately 1 more active screen culture performed (mean [ⳲSD] of 0.97 Ⳳ 1.87 CAS cultures and
2.8 Ⳳ 1.5 CAS swab samples per patient), compared with
patients colonized with enteric VRE on admission (mean
[ⳲSD] of 0.38 Ⳳ 0.91 CAS cultures and 1.8 Ⳳ 0.85 CAS
swab specimens per patient) and patients who remained negative for VRE through discharge (mean [ⳲSD] of 0.24 Ⳳ
0.74 CAS cultures and 1.6 Ⳳ 1.0 CAS swab specimens per
patient). In total, 309 patients (17%) were VRE colonized;
182 (59%) had VRE detected on admission (prevalent cases),
and 127 patients (41%) acquired VRE (incident cases) (Table
3).
Among VRE-colonized patients, VRE was initially detected
in 280 (91%) by CAS, in 25 (8%) by LAS, and in 4 (1%) by
analysis of clinical specimens. The incidence density of VRE
was 12.7 cases of acquired VRE per 1,000 ICU patient-days.
VRE in most (100 [79%]) of the 127 patients who acquired
VRE was detected by CAS. The LAS method alone would
have missed 234 cases of enteric colonization with VRE
(76%), 144 (62%) of which were prevalent cases and 90 (38%)
of which were incident cases. Three cases (1%) would not
have been identified without LAS. A consistent pattern of
VRE surveillance occurred (Figure). Approximately 20 LAS
screening cultures per month were completed, compared with
116 CAS screening cultures per month. Screening on ad-
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figure.
Comparison of clinical active surveillance (CAS) with laboratory-based active surveillance (LAS), by number of cultures
performed and number of cultures with positive results, at Barnes-Jewish Hospital during a 30-month period. See Methods for definitions
of CAS and LAS.

mission detected 59% of the patients in our sample who were
colonized with VRE, and an additional 36 patients (12%)
with colonization would have been detected by LAS at some
point during the ICU stay. The percentage of patients from

whom specimens were procured for CAS at admission was
93% (1,734 of 1,872 patients), whereas the percentage at discharge was 53% (984 patients). Forty-one percent of patients
(766) had only one surveillance test performed, and among

table 4. Characteristics of Surveillance Performed for 5 Patients for Whom Results of Cultures for Detection of Vancomycin-Resistant
Enterococci Varied During Hospitalization
Patient,
surveillance
characteristic
Patient 1
Type
Test result
Datea
Patient 2
Type
Result
Datea
Patient 3
Type
Result
Datea
Patient 4
Type
Result
Datea
Patient 5
Type
Result
Datea
note.
a

Swab sample tested
Admission

No. 2

No. 3

No. 4

No. 5

No. 6

No. 7

No. 8

LAS
Positive
12/19

LAS
Negative
12/22

CAS
Negative
12/23

LAS
Negative
12/24

LAS
Negative
12/25

LAS
Positive
1/2

LAS
Positive
1/3

LAS
Positive
1/4

CAS
Negative
1/11

CAS
Negative
1/15

CAS
Positive
2/2

LAS
Negative
2/6

CAS
Positive
2/7

CAS
Negative
2/25

CAS
Negative
10/21

LAS
Negative
10/2

CAS
Negative
11/8

LAS
Negative
11/20

LAS
Positive
11/21

CAS
Positive
11/23

CAS
Negative
2/3

CAS
Negative
2/10

LAS
Positive
2/15

CAS
Negative
2/17

CAS
Positive
2/23

CAS
Positive
2/25

CAS
Negative
5/22

CAS
Negative
6/2

CAS
Negative
6/10

CAS
Positive
6/22

CAS
Negative
6/28

…
…
…

…
…
…

Discharge
CAS
Positive
1/16

…
…
…

CAS
Negative
2/26

CAS
Negative
11/24

…
…
…

CAS
Negative
11/29

LAS
Negative
3/3

…
…
…

CAS
Negative
3/4

…
…
…

CAS
Negative
7/2

…
…
…

See Methods for definitions of clinical active surveillance (CAS) and laboratory-based active surveillance (LAS).
Date on which swab sample was collected.
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table 5. Estimated Cost Savings of Clinical Active Surveillance (CAS), Compared
With Laboratory-Based Active Surveillance, During a 30-Month Period, According to
Estimated Averted Cases of Vancomycin-Resistant Enterococci (VRE) Colonization and
Associated Bacteremia
Cost savings associated with
use of CAS, 2003 US$
Variable
Incremental MICU colonization cost savings for levels
of transmission (0.5-2) of undetected VRE
Excess cost of colonization p $3,065a
0.50
1.00
1.50
2.00
Excess cost of colonization p $9,970b
0.50
1.00
1.50
2.00
Likelihood of colonized patient becoming bacteremic
Increased cost of VRE bacteremia p $17,143c
7.8%
13%
Increased cost of VRE bacteremia p $36,380d
7.8%
13%

During 30-mo
study period

Per month

1,062,023
1,416,030
1,770,038
2,124,045

35,401
47,201
59,001
70,802

3,454,605
4,606,140
5,757,675
6,909,210

115,154
153,538
191,923
230,307

625,720
1,032,351

20,857
34,412

1,327,870
2,190,804

44,262
73,027

note. We assumed a transmission rate of 1.00 (ie, that each case patient with VRE transmitted
VRE to one other person). See Methods for definitions of clinical active surveillance (CAS) and
laboratory-based active surveillance (LAS). MICU, medical intensive care unit.
a
From Montecalvo et al.40
b
From Puzniak et al.25
c
From Carmelli et al.13
d
From Stosor et al.8

the patients for whom a discharge surveillance test was not
performed, 381 (43%) of 888 stayed in the ICU for less than
72 hours, and 242 (27%) of 888 died while in the ICU.
Atypical Test Results
Among patients who tested positive for enteric VRE, all but
20 (8%) of 237 patients for whom 2 or more tests were
performed remained VRE positive throughout their ICU stay.
Five patients (0.02%) displayed atypical results of cultures,
with oscillations between negative and positive results for
enteric colonization with VRE (Table 4). Nine patients who
stayed in the ICU for less than 48 hours had an initial culture
that was positive for VRE and a discharge culture that was
negative for VRE. In addition, 6 patients with varying numbers of VRE-positive test results had a single surveillance test
that was negative for enteric VRE at ICU discharge.
Programmatic Costs
The total cost estimated for both the CAS and LAS programs
in 2003 dollars was $67,958 for 30 months. The LAS costs

were $10,563, whereas the CAS costs were $57,395. These
estimates include allocated and direct costs, which may vary
among different institutions. Estimated monthly costs for VRE
surveillance were $1,913 for CAS and $352 for LAS (Table
2). The cost was $30.66 per patient for CAS and $5.64 per
patient for LAS. An additional 337 VRE cultures were performed subsequent to a culture that yielded enteric VRE. A
30-month cost savings of $10,367 would have been realized
if VRE surveillance was terminated after a positive test result
was documented. The associated costs of VRE surveillance
would have been $1,568 per month for CAS ($25.12 per
patient) if the cost of these 337 cultures was excluded.
Estimated Cost Savings
The CAS method requires the performance of 4.7 times more
cultures than the LAS method (Table 3). The LAS method
alone would not have identified 234 cases of VRE colonization, whereas the CAS method identified all but 3 cases of
VRE colonization. Use of CAS would prevent 346.5-693 cases
of VRE colonization, depending on the transmission dynamic
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of VRE, and 36.5-60.22 cases of bacteremia. By applying excess cost estimates for colonization and bacteremia, adjusted
to 2003 dollars,40 and varying the VRE transmission rate,
prevention of colonization by use of CAS would have an
estimated cost savings ranging from $35,401 to $230,307 per
month, relative to the cost associated with the LAS method
(Table 5).5,21,25 Assuming that 1 case patient with VRE transmits VRE to 1 other person and that, of those colonized with
VRE, between 8% and 13% become VRE bacteremic, the
estimated cost savings attributable to prevented bacteremia
ranges from $20,857 to $73,027 per month.8,13 Taken together,
the total estimated cost savings associated with use of CAS
ranges from $56,258 to $303,334 per month.

dis c us s i on
These data suggest that strategic CAS was superior to LAS
for detecting enteric colonization with VRE in an ICU where
VRE is endemic. The excess costs of surveillance were modest
relative to the estimated averted costs of associated infections.
Colonization in most (91%) of the VRE-colonized participants was initially identified by CAS, a method of surveillance
that routinely surveys the population at risk, prospectively
identifies acquired cases, and allows for the calculation of
colonization pressure.6,38 In contrast, the C. difficile specimen–
associated LAS missed most cases of colonization (76%) in
patients colonized with VRE.31,32,34 We propose that the focused screening of submitted C. difficile specimens for VRE
may be appropriate for institutions or units within institutions with historically low rates of VRE colonization and
limited resources.43 In such algorithms, if LAS determines an
increase in the prevalence of VRE colonization, then endemicity may indicate a need for transition to a CAS method.
Overall, the total costs for the CAS program (estimated to
be $1,913 monthly) were minimal, compared with the estimated averted excess costs attributable to preventing VRE
colonization and bacteremia. The estimated cost savings of
CAS attributable to preventing VRE colonization and bacteremia ranged from $56,258 to $303,334 per month. The
large variation resulted from different assumptions about the
VRE transmission rate, the likelihood of a colonized patient
becoming bacteremic, and the increased hospital costs attributable to colonization and bacteremia. Despite the large
variation, all cost-saving estimates greatly exceed the monthly
costs of implementing CAS. Of note, the third-party payer
and societal costs were likely significant and were not accounted for in the resources estimated herein. The additional
benefits of placing patients in isolation to reducing transmission of other transmissible agents, such as extended-spectrum b-lactamase–producing bacteria, were not assessed.42
Furthermore, because most VRE-colonized patients remained
colonized with this pathogen, the incremental cost of the CAS
and LAS methods would decrease if subsequent testing did
not occur after the initial positive test result was available,
for an estimated cost savings of $10,367.

We recognize the study limitation associated with decreased
compliance with performing surveillance cultures at ICU discharge (53% of patients), which was low compared with the
percentage of patients (93%) who had cultures performed at
ICU admission; thus, incidence rates for enteric colonization
with VRE were likely to be underestimated. In addition, costto-charge ratios were not calculated because of difficulties
with estimating reimbursements received and because actual
hospital costs are better indicators of economic costs.44 Finally, placement of a patient in isolation occurred when a
patient was culture positive for VRE, not at admission, limiting an evaluation of direct patient-to-patient transmission.
Colonization pressure for this subset of patients has previously been used to estimate transmission likelihoods.6 In summary, we propose that LAS can be used in a prevalence-based
approach to enteric VRE surveillance in low-risk, low-incidence settings, whereas in high-risk settings, such as ICUs
and other units with high colonization pressure for VRE, CAS
surveillance seems most efficient and cost-effective.
Address reprint requests to Brooke N. Shadel, PhD, MPH, Saint Louis University, School of Public Health, Saint Louis, MO 63104 (shadebn@slu.edu).

acknowledgments
We thank the 65 members of the medical intensive care unit staff, the BarnesJewish Hospital medicine residents, and the Washington University faculty
who participated in the care of these patients; Jennie Mayfield and Donna
Prentice for managing the surveillance for vancomycin-resistant Enterococcus
surveillance; Terry Leet for epidemiological input; and Joan Hoppe-Bauer
for the provision of microbiology data. We acknowledge the assistance of
Dr. Thomas Bailey and the Washington University Medical Informatics Laboratory for assistance with the electronic harvest of the clinical data.

re f e re n c e s
1. Edmond MB, Ober JF, Dawson JD, et al. Vancomycin-resistant enterococcal bacteremia: natural history and attributable mortality. Clin Infect
Dis 1996; 23:1234-1239.
2. Lucas GM, Lechtzin N, Puryear DW, et al. Vancomycin-resistant and
vancomycin-susceptible enterococcal bacteremia: comparison of clinical
features and outcomes. Clin Infect Dis 1998; 26:1127-1133.
3. Linden PK, Pasculle AW, Manez R, et al. Differences in outcomes for
patients with bacteremia due to vancomycin-resistant Enterococcus faecium
or vancomycin-susceptible E. faecium. Clin Infect Dis 1996; 22:663-670.
4. Jernigan JA, Clemence MA, Stott GA, et al. Control of methicillinresistant Staphylococcus aureus at a university hospital: one decade later.
Infect Control Hosp Epidemiol 1995; 16:686-696.
5. Muto CA, Giannetta ET, Durbin LJ, et al. Cost-effectiveness of perirectal
surveillance cultures for controlling vancomycin-resistant Enterococcus.
Infect Control Hosp Epidemiol 2002; 23:429-435.
6. Puzniak LA, Leet T, Mayfield J, et al. To gown or not to gown: the effect
on acquisition of vancomycin-resistant enterococci. Clin Infect Dis 2002;
35:18-25.
7. Song X, Srinivasan A, Plaut D, et al. Effect of nosocomial vancomycinresistant enterococcal bacteremia on mortality, length of stay, and costs.
Infect Control Hosp Epidemiol 2003; 24:238-241.
8. Stosor V, Peterson LR, Postelnick M, et al. Enterococcus faecium bacteremia; does vancomycin resistance make a difference? Arch Intern Med
1998; 158:522-527.
9. Muto CA, Jernigan JA, Ostrowsky BE, et al. SHEA guideline for pre-

active surveillance for vre

10.

11.

12.
13.

14.
15.

16.

17.

18.

19.

20.

21.

22.

23.

24.

25.

26.
27.

venting nosocomial transmission of multidrug-resistant strains of Staphylococcus aureus and Enterococcus. Infect Control Hosp Epidemiol 2003;
24:362-386.
Centers for Disease Control and Prevention. Brief report: vancomycinresistant Staphylococcus aureus—New York, 2004. MMWR Morb Mortal
Wkly Rep 2004; 53:322-323.
DiazGranados CA, Zimmer SM, Klein M, Jernigan JA. Comparison of
mortality associated with vancomycin-resistant and vancomycin-susceptible blood stream infections: a meta-analysis. Clin Infect Dis 2005; 41:
327-333.
Boyce JM. Consequences of inaction: importance of infection control
practices. Clin Infect Dis 2001; 33(Suppl 3):S133–S137.
Carmeli Y, Eliopoulos G, Mozaffari E, et al. Health and economic outcomes of vancomycin-resistant enterococci. Arch Intern Med 2002; 162:
2223-2228.
Holmberg SD, Solomon SL, Blake PA. Health and economic impacts of
antimicrobial resistance. Rev Infect Dis 1987; 9:1065-1078.
US Congress, Office of Technology Assessment. Impacts of AntibioticResistant Bacteria. Washington, DC: US Government Printing Office;
September 1995. OTA-H-62.
Montealvo MA, Horowitz H, Gedris C, et al. Outbreak of vancomycin, ampicillin-, and aminoglycoside-resistant Enterococcus faecium bacteremia in an adult oncology unit. Antimicrob Agents Chemother 1994; 38:
1363-1367.
Roghmann MC, McCarter RJ Jr, Brewrink J, et al. Clostridium difficile
infection is a risk factor for bacteremia due to vancomycin-resistant
enterococci (VRE) in VRE-colonized patients with acute leukemia. Clin
Infect Dis 1997; 25:1056-1059.
Zaas AK, Song X, Tucker P, et al. Risk factors for development of vancomycin-resistant enterococcal bloodstream infection in patients with
cancer who are colonized with vancomycin-resistant enterococci. Clin
Infect Dis 2002; 35:1139-1146.
Willems RJ, Top W, van Santen M, et al. Global spread of vancomycinresistant Enterococcus faecium from distinct nosocomial genetic complex.
Emerg Infect Dis 2005; 11:821-828.
Hospital Infection Control Practices Advisory Committee. Recommendations for preventing the spread of vancomycin resistance: Hospital
Infection Control Practices (HICPAC). Infect Control Hosp Epidemiol
1995; 16:105-113.
Edmond MB. Cost-effectiveness of perirectal surveillance cultures for
controlling vancomycin-resistant Enterococcus. Infect Control Hosp Epidemiol 2003; 24:309-310.
Leber AL, Hindler JF, Kato EO, et al. Laboratory-based surveillance for
vancomycin resistant enterococci: utility of screening stool specimens
submitted for Clostridium difficile toxin assay. Infect Control Hosp Epidemiol 2001; 22:160-164.
Mayhall CG. Control of vancomycin-resistant enterococci: it is important, it is possible, and it is cost-effective. Infect Control Hosp Epidemiol
2002; 23:420-423.
Hachem R, Graviss L, Hanna H, et al. Impact of surveillance for vancomycin-resistant enterococci on controlling a bloodstream outbreak
among patients with hematologic malignancy. Infect Control Hosp Epidemiol 2004; 25:391-394.
Puzniak LA, Gillespie KN, Leet T, et al. A cost-benefit analysis of gown
use in controlling vancomycin-resistant Enterococcus transmission: is it
worth the price? Infect Control Hosp Epidemiol 2004; 25:418-424.
Jarvis WR. Controlling antimicrobial-resistant pathogens. Infect Control
Hosp Epidemiol 2004; 25:369-371.
Price CS, Paule S, Noskin GA, Peterson LR. Active surveillance reduces

28.

29.

30.

31.

32.

33.

34.

35.

36.

37.

38.

39.

40.

41.
42.

43.

44.

1075

the incidence of vancomycin-resistant enterococcal bacteremia. Clin Infect Dis 2003; 37:921-928.
Calfee DP, Giannetta ET, Durbin LJ, Germanson TP, Farr BM. Control
of endemic vancomycin-resistant Enterococcus among inpatients at a university hospital. Clin Infect Dis 2003; 37:326-332.
Puzniak LA, Mayfield, Leet T, et al. Acquisition of vancomycin-resistant
enterococci during scheduled antimicrobial rotation in an intensive care
unit. Clin Infect Dis 2001; 33:151-157.
Byers KE, Anglim AM, Anneski CJ, et al. Duration of colonization with
vancomycin-resistant Enterococcus. Infect Control Hosp Epidemiol 2002;
23:207-211.
Hacek DM, Patrice B, Noskin GA, et al. Yield of vancomycin-resistant
enterococci and multidrug-resistant Enterobacteriaceae from stools submitted for Clostridium difficile testing compared to results from a focused
surveillance program. J Clin Microbiol 2001; 39:1152-1154.
Katz KC, Gardam MA, Burt JB, et al. A comparison of multifaceted
versus Clostridium difficile–focused VRE surveillance strategies in a lowprevalence setting. Infect Control Hosp Epidemiol 2001; 22:219-221.
Perencevich EN, Fisman DN, Lipsitch M, Harris AD, Morris JG Jr, Smith
DL. Projected benefits of active surveillance for vancomycin-resistant
enterococci in intensive care units. Clin Infect Dis 2004; 38:1108-1115.
Ray AJ, Hoyen CK, Das SM, et al. Undetected vancomycin-resistant
Enterococcus stool colonization in a veterans affairs hospital using a Clostridium difficile–focused surveillance strategy. Infect Control Hosp Epidemiol 2002; 23:474-477.
Sahm DR, Free L, Smith C, et al. Rapid characterization schemes for
surveillance isolates of vancomycin-resistant enterococci. J Clin Microbiol
1997; 35:2026-2030.
Kahn MG, Steib SA, Dunagan WC, et al. Monitoring expert system
performance using continuous feedback. J Am Med Inform Assoc 1996;
3:216-233.
US Department of Labor, Bureau of Labor Statistics. Consumer Price
Index for Medical Care. Washington, DC: US Department of Labor, Bureau of Labor Statistics; 2003. Available at http://www.bls.gov/cpi/. Accessed: May 15, 2005.
Bonten MJ, Slaughter S, Ambergen AW, et al. The role of “colonization
pressure” in the spread of vancomycin-resistant enterococci: an important infection control variable. Arch Intern Med 1998; 158:1127-1132.
Roghmann MC, Qaiyumi S, Schwalbe R, et al. Natural history of colonization with vancomycin-resistant Enterococcus faecium. Infect Control
Hosp Epidemiol 1997; 18:679-680.
Montecalvo MA, Jarvis WR, Uman J, et al. Costs and savings associated
with infection control measures that reduce transmission of vancomycinresistant enterococci in an endemic setting. Infect Control Hosp Epidemiol
2001; 22:437-442.
Knaus WA, Draper EA, Wagner DP, Zimmerman JE. APACHE II: a
severity of disease classification system. Crit Care Med 1985; 13:818-829.
Harris AD, Nemoy L, Johnson JA, et al. Co-carriage rates of vancomycinresistant Enterococcus and extended-spectrum beta-lactamase–producing
bacteria among a cohort of intensive care unit patients: implications for
an active surveillance program. Infect Control Hosp Epidemiol 2004; 25:
105-108.
Division of Healthcare Quality Promotion, National Center for Infectious
Diseases, Centers for Disease Control and Prevention. National nosocomial infections surveillance (NNIS) system report, data summary from
January 1992 through June 2003, issued August 2003. Am J Infect Control
2003; 31:481-498.
Finkler SA. The distinction between cost and charges. Ann Intern Med
1982; 96:102-109.

